Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.International biopharmaceutical firm Coley Pharmaceutical Group has obtained positive tumor response data from a phase II clinical study of ProMune plus chemotherapy in non-small cell lung cancer.
Subscribe to our email newsletter
The randomized, controlled phase II study was designed to evaluate improved response when ProMune is added to standard chemotherapy compared to chemotherapy alone, in first-line treatment of advanced non-small cell lung cancer (NSCLC).
Patients receiving ProMune plus standard chemotherapy (taxane and platinum) achieved objective (RECIST criteria) tumor responses more often than patients given chemotherapy alone.
These improved tumor responses are also now evident in a positive trend in prolongation of both progression-free survival and overall survival in this difficult-to-treat cancer.
ProMune is the first of a new class of investigational medicines known as TLR therapeutics being developed by Coley Pharmaceutical for the treatment of major medical conditions including cancer, infectious diseases, allergy and asthma. These chemically defined and well characterized drugs target toll-like receptors (TLRs) which are principal sentinels for the body’s immune system.
Final data from the study will be presented later this year.